TCTR20190827001尚未招募1 期
An open label, single dose, randomized, two-formulation, two-period, two-sequence crossover study with 5 weeks (35 days) washout period
T.O. Chemicals (1979) Ltd.0 个研究点目标入组 34 人开始时间: 2019年8月27日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- Male
入选标准
- •1.Male must be 18-55 years of age, body mass index (BMI) = 18.0-25.0 kg/m2, inclusive.
- •2.Must be in good health as determined by medical history, vital signs (blood pressure (systolic blood pressure not lower than 90 or not over 129 mmHg, diastolic blood pressure not lower than 60 or not over 79 mmHg), body temperature, pulse rate, respiratory rate) and physical examination
- •3.Screening electrocardiography (ECG) without clinically significant abnormalities
- •4.Screening visit laboratory values of blood test including hematology (complete blood count (CBC) with differential), fasting blood sugar (FBS), blood urea nitrogen (BUN), creatinine (Cr) and liver function test (aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin and alkaline phosphatase (ALP)) must be within the normal range or showing no clinically significant abnormalities in the opinion of clinical investigator.
- •5.Urinalysis results within normal limit or showing no clinically significant abnormalities in the opinion of clinical investigator.
- •6.Must have serum hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV) and human immunodeficiency virus antibody (anti-HIV) seronegative
- •7.Subject agrees to use an acceptable birth control method from visit 1 to the follow-up visit. The acceptable birth control method is defined as a barrier method of contraception (including condoms) or total abstinence from sexual intercourse from visit 1 to the follow-up visit.
- •8.Non-smokers (never smoked or no smoking within the previous 1 years)
- •9.Refrain from using herbal medications, dietary supplements (e.g., St. John’s Wort, ginkgo biloba, garlic supplements), vitamins, grapefruit or grapefruit juice, or pomelo within 14 days before the first administration of study drug (Day 1). Subjects must agree to refrain from these items until the last collection time-point of period 2.
- •10.Subjects must have ended any medications at least 30 days prior to Day 1 and agree to continue their refraining throughout the follow-up period.
- •11.Subjects must refrain from drinking caffeine and alcohol for at least 72 hours prior to Day 1 and agree to continue their refraining throughout the last collection time-point of period 2.
- •12.Have the ability to understand the requirements of the study and must voluntarily sign and date an informed consent, approved by an Independent Ethic Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures
排除标准
- •1.Known hypersensitivity to dutasteride, any other similar class of drugs and its components
- •2.Past medical history of renal and hepatic insufficiency
- •3.Subject has a history of any illness that, in the opinion of the investigator, might confound the result of the study or pose an additional risk in administering study drug to the subject. This may include but is not limited to: a history of relevant drug or food allergies; history of cardiovascular, gastrointestinal, central nervous system disease, renal and hepatic impairment; history or presence of clinically significant illness; or history of mental illness that may affect compliance with study requirements.
- •4.Have history of drug abuse (in the opinion of the investigator, as judged by medical history) in the last 12 months
- •5.Have positive result of urine drug abuse testing on opioids (morphine (Mor), methadone (MTD)), cannabiniods (tetrahydrocannabinol (THC)), methamphetamine (Meth), cocaine (Coc) and methylenedioxy-methamphetamine (MDMA) at screening visit or before dose administration at each period
- •6.Alcohol abuse or excessive use (in the opinion of the investigator, as judged by medical history) in the last 12 months
- •7.Have positive result of alcohol breathing test at screening visit or before dose administration at each period
- •8.Difficulties fasting or consuming standard meals
- •9.Difficulties swallowing whole tablets
- •10.Donation or loss of whole blood:
- •a.≥ 50 mL and ≤ 499 mL within 30 days prior to dosing
- •b.≥ 500 mL within 56 days prior to dosing.
- •11.Participation in any investigation drug study within 1 month prior to screening visit
研究者
相似试验
尚未招募
1 期
A Bioequivalence Study of Two Formulations of Sitagliptin Phosphate Film-coated Tablet Equivalent to 100 mg Sitagliptin in Healthy Thai Volunteers under Fasting ConditionsHealthy volunteersSitagliptinBioequivalencePharmacokineticsTCTR20200108002ovartis (Thailand) Ltd.32
尚未招募
1 期
A Bioequivalence Study of Two Formulations of 40-mg Pantoprazole (as Pantoprazole Sodium Sesquihydrate) Gastro-resistant Tablets in Healthy Thai Volunteers under Fed ConditionsHealthy volunteersPantoprazoleBioequivalencePharmacokineticsTCTR20200116005T.O. Chemicals (1979) Ltd.32
尚未招募
1 期
A single dose, randomized, open-label, two-way crossover Bioequivalence study of Duloxetine delayed release capsules USP 60 mg relative to Cymbalta® (60 mg hard gastro-resistant capsules duloxetine) in healthy Thai volunteers under fasting and fed conditionsHealthy VolunteerTCTR20200313007International Bio Service Co., Ltd32
尚未招募
不适用
A single dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Etoricoxib 90 mg Film-coated Tablets and reference Product (ARCOXIA) in healthy Thai Volunteers under Fasting conditionsBioequivalence studyTCTR20190228002Polipharm Co., Ltd.28
已完成
不适用
A single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Etoricoxib 120 mg Film-coated Tablets and Reference Product (ARCOXIA) in Healthy Thai Volunteers under Fasting ConditionsFor bioequivalence studied by compare the rate and extent of absorption of test formulation and reference formulation,including evaluate safety of test and reference formulation.-EtoricoxibBioequivalenceTCTR20181024004International Bio Service Co., Ltd.28